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Abstract
Background: The INSIG2 gene has been implicated in cholesterol metabolism and a single nucleotide
polymorphism (SNP) near INSIG2 has been shown to be associated with obesity. We sought to determine the
relationship of the INSIG2 SNP to cardiovascular disease (CVD) related phenotypes.
Methods and Results: Nine hundred forty six patients undergoing percutaneous coronary intervention (PCI) in
wave 5 of the multicenter NHLBI Dynamic Registry were genotyped using RT-PCR/TaqMan/allelic discrimination for
the rs7566605 SNP near the INSIG2 gene. Clinical variables analyzed include demographics, medical history, and
procedural details. The prevalence of peripheral vascular disease (PVD) was significantly higher in older men (≥65
years) who were either homozygous or carriers of the obesity/lipid risk allele ("C”) compared to non-carriers (odds
ratio 3.4, p = 0.013) using a logistic regression model incorporating history of hypercholesterolemia, history of
hypertension, cerebrovascular disease, history of diabetes, and BMI. A similar relationship with cerebrovascular
disease was found in older (>65) women (odds ratio 3.4, p = 0.013). The INSIG2 SNP was not associated with BMI,
nor with other clinical variables.
Conclusion: Age and gender may influence the association of the INSIG2 obesity SNP with PVD and
cerebrovascular disease in patients with pre-existing CVD.
Background
Risk factors for atherosclerosis related disorders include
dyslipidemia and obesity. The insulin signaling protein
type 2 gene (INSIG2) has been shown to be involved in
lipid and cholesterol metabolism in vitro and in animal
studies [1-3], and has been linked to obesity in humans
through genetic studies. For example, INSIG2 interacts
with transcription factors that activate the synthesis of
cholesterol and fatty acids in the liver and other organs
[4]. In addition, a common single nucleotide poly-
morphism (SNP rs7566605) near the INSIG2 gene was
found to be associated with BMI in a genome-wide
association study from the Framingham Heart Study off-
spring cohort [5]. Playing both a key role in cholesterol
homeostasis and as a genetic susceptibility factor for
obesity makes it an attractive candidate locus for lipid-
related phenotypes such as cardiovascular disease, as
well as for BMI.
The initial association of BMI with homozygosity for
the minor allele of the INSIG2 rs7566605 SNP was fol-
lowed by both negative and positive associations invol-
ving analysis of many thousands of individuals [6-9].
Studies in severe obesity have also failed to associate the
SNP with blood lipid parameters [10,11], although medi-
cation use (e.g., statins) was not accounted for. However,
in populations with lower BMI levels, a gender effect
may be present [12,13]. Little or no association has been
f o u n dw i t hc o r o n a r ya r t e r yd isease in population-based
studies [10,14-16], nor with obesity in cohorts recruited
for cardiovascular phenotypes [6]. The goal of this study
was to determine the relationship between the INSIG2
rs7566605 SNP and multiple cardiovascular phenotypes
in a well-characterized population of patients with
known coronary artery disease.
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Population
The National Heart Lung and Blood Institute-sponsored
Dynamic Registry was utilized for this study. In brief,
the multi-center Dynamic Registry was designed to
characterize changes in clinical practice, particularly
evolving technology, on short- and long-term patient
outcomes. Five recruitment waves of approximately
2000 patients each have been enrolled and followed over
the past 10 years to examine trends in PCI. Each center
received approval from its institutional review board. No
control patients not undergoing PCI were included in
the study.
This analysis was restricted to Wave 5 patients
recruited from February 2006 to August 2006 who con-
sented to the genomic sub-study. Of the 15 Wave 5
clinical centers, 11 participated in the collection of
blood samples. The study population consisted of 947
patients, 70.6% of whom were male with a median age
64 years and a median BMI of 29.0 kg/m
2,i nw h o ma t
least one stent had been placed with a yearly post-pro-
cedure follow-up scheduled to 5 years. The racial/ethnic
distribution was 77.7% Caucasian, 14.0% African Ameri-
can, 1.1% Asian, and 7.0% Hispanic. Approximately
35.3% of patients never smoked, 24.1% were current
smokers at the time of enrollment, and 40.6% were for-
mer smokers. A history of hypertension was found in
78.2%, hypercholesterolemia in 79.4%, a prior myocar-
dial infarction in 24.8%, cerebrovascular disease in 7.0%,
renal disease in 9.9%, peripheral vascular disease (PVD)
in 7.5%, pulmonary disease in 8.1%, cancer in 8.5%, and
diabetes in 37.4%.
Of the 947 patients in Wave 5 consented for the geno-
mics sub study, 821 (86.7%) received only drug-eluting
stents, 48 (5.1%) received bare-metal stents only, 39 (4.1%)
received both a drug-eluting stent and a bare-metal stent
and 39 (4.1%) received balloon angioplasty alone.
Data
Data collected included baseline demographic, clinical,
and angiographic characteristics and procedural details
during the index PCI, as well as the occurrence of death,
myocardial infarction, and the need for coronary-artery
bypass grafting (CABG) during hospitalization. A blood
draw for genomic analysis was added to Wave 5 and was
obtained in dually consented patients (n = 947). Follow-
up status was ascertained at 1 month, 6 months, and
annually thereafter. The follow-up rate at 1 year was 97%.
With the use of the Social Security Administration’s
Death Master File (http://www.ntis.gov/products/ssa-
dmf.aspx), coordinators periodically evaluated the vital
status of patients who were lost to follow-up. For patients
who underwent subsequent repeat revascularization
(either PCI or CABG), vessel-specific and lesion-specific
data were collected whenever possible to determine the
occurrence of target-vessel revascularization.
DNA isolation
DNA was extracted from 0.35 ml of EDTA anti-coagu-
lated whole blood using the Qiagen MagAttract DNA
Blood Midi M48 Kit and Qiagen BioRobot M48 Work-
station (Qiagen, Valencia, CA) according the manufac-
turer’s directions. The final elution volume was 200 ul.
Quantification of DNA extracted was performed using a
NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE).
Genotyping
Single nucleotide polymorphism (SNPs) genotyping was
performed on an Applied Biosystems 7500 real-time
PCR System (Applied Biosystems, Foster City, CA)[17].
Assay reagents for each SNP were obtained from
Applied Biosystems (INSIG2, rs7566605, assay ID:
C__29404113_20). DNA was genotyped according to the
manufacturer’s protocol. Briefly, the reaction compo-
nents for each genotyping reaction were as follows: 10
ng of DNA, 5 μL of TaqMan Genotyping Master Mix
(Applied Biosystems, Foster City, CA), 0.25 μLo fa s s a y
mix (40×), and water up to a total volume of 10 μL. The
thermocycler conditions were as follows: 50°C for 2 min,
95°C for 10 min, and 40 cycles of 95°C for15 sec and 60°
C for 60 sec. The reaction was then analyzed by Applied
Biosystems Sequence Detection Software (version 2.01).
Statistical analysis
All statistical analyses were performed with the use of
SAS software, version 9.1, and a two-sided P value of
≤0.05 was considered to indicate statistical significance.
Differences in baseline characteristics between the
groups were detected using a Chi-Square test for the
categorical variables and a T-test for the continuous
variables when 2 groups are present. ANOVA was used
for testing differences among 3 or more groups of con-
tinuous variables. One year cumulative event rates of
clinical outcomes (MI, CABG, repeat PCI, Stent Throm-
bosis and composite outcomes (MI/CABG, CABG/rep
PCI, MI/CABG/rep PCI) were estimated by the Kaplan-
Meier method and tested by the log-rank statistic. Fish-
er’s exact test was used to test INSIG2 genotypes for
departure from Hardy-Weinberg equilibrium using the
Helix Tree software package (Golden Helix, Bozeman,
MT).
Four age and gender groups were analyzed using a
stepwise logistic regression model to estimate the inde-
pendent effects of different variables of interest, as well
as the INSIG2 genotype. For men >= 65 years of age,
PVD was close to being significant. The odds ratio of
the CC_GC genotype from the model was adjusted for
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cerebrovascular disease, history of diabetes, and BMI.
For men < 65 years of age, history of hypercholesterole-
mia was close to being significant. A similar analysis
was used to adjust the odds ratio of the CC_GC geno-
type. The additional variables in the model that were
adjusted for were PVD, history of hypertension, cerebro-
vascular disease, history of diabetes, and BMI. For
women >= 65 years of age, cerebrovascular disease was
close to being significant. The additional variables the
model was adjusted for were: history of hypercholestero-
lemia, PVD, history of diabetes, and BMI. For women <
65 years of age, history of hypercholesterolemia was
close to being significant. The additional variables the
model was adjusted for were PVD, history of hyperten-
sion, history of cerebrovascular disease, history of dia-
betes, and BMI.
Results
DNA samples were genotyped for the INSIG2
(rs7566605) SNP variant. Genotyping consisted of ana-
lyzing the DNA from each patient to determine whether
they carried the “G” and/or “C” DNA sequences near
the INSIG2 gene. The INSIG2 “C” SNP is considered
the ‘obesity/lipid risk’ allele. The frequency of the
INSIG2 SNP in this population is shown in Table 1 and
is in good agreement with previous studies [9]. The gen-
otype distribution did not deviate from Hardy-Weinberg
equilibrium (p = 0.82). Because patients with African
ancestry represent the largest single racial/ethnic sub-
group (Table 2), we compared the allele frequency of
our population with available data from the HapMap
(http://www.hapmap.org). Very little difference in allele
frequency was present among Caucasian and African
populations.
The diploid INSIG2 SNP genotypes (i.e., “CC”, “GC”,
and “GG”) were also analyzed (Table 2). The INSIG2
homozygous “CC” genotype was present in ~10% of the
population. The INSIG2 heterozygous “GC” genotype
was present at 43.6% and the INSIG2 low obesity risk
“GG” was present in 46.5%. Genotype breakdown by
ethnic/racial sub-group is also presented.
We then determined whether the frequencies of the
more than 30 clinical parameters (Table 3) related to
coronary artery disease and stent placement were
different among patients with the three INSIG2 obesity/
lipid SNP genotypes. No differences, either before or
after correcting for multiple comparisons, were present
in BMI across genotype groups. No significant differ-
ences were present among the genotypes for gender,
race/ethnicity, or smoking status. The percentage of
patients undergoing a prior stent placement or CABG,
as well as the percentage with a history of in-stent reste-
nosis or the type of stent implanted was also not differ-
ent among the genotypes. Although the percentages of
patients with a history of prior MI and a history of cere-
brovascular disease were different prior to Bonferroni
correction, they did not reach significance after correc-
tion. No differences were seen for histories of diabetes,
renal disease, chest pain, PVD, pulmonary disease, can-
cer, hypercholesterolemia, or hypertension.
Further inspection of the data revealed that the high-
est percentage of patients with a history of prior MI
were the patients homozygous for the “CC” obesity/lipid
risk allele. Similarly, patients who were either “CC”
homozygotes or “GC” heterozygotes had the higher per-
centage of a history of cerebrovascular disease. There
was also a trend for patients with a history of PVD to
have the C allele. A dominant model was therefore used
to analyze the data by comparing patients homozygous
for the non-risk genotype ("GG”) versus the patients
carrying at least one obesity/lipid risk “C” allele ("GC”
plus “CC”). Because of the strong influence of gender
and age on coronary artery disease, the data were also
r e - a n a l y z e db ya g ea n dg e n d e r( T a b l e4 ) .I nm e n≥65
years of age, the percent with a history of PVD was
almost three-fold higher in patients carrying one or two
“C” alleles (Bonferroni adjusted p = 0.05). Conversely in
women ≥65 years of age, the percent with a history of
cerebrovascular disease was also higher in patients car-
rying one or two “C” alleles, although this was close to,
but did not reach, statistical significance after correcting
for multiple comparisons. These data suggest a sex-
related effect of the INSIG2 obesity/lipid allele.
A stepwise logistic regression was then used to esti-
mate the independent effects of different variables, as
well as the INSIG2 genotype, on PVD in men ≥65 years
and cerebrovascular disease in women ≥65 years, as well
as history of hypercholesterolemia for both women and
m e n<6 5y e a r so fa g e .A ss h o w ni nT a b l e5 ,t h e
Table 1 Frequencies of the INSIG2 SNP alleles
Population allele freq count allele freq count Total
Caucasian C 0.331 515 G 0.669 1041 1556
AA C 0.243 66 G 0.757 206 272
Utah C 0.265 60 G 0.735 166 226
Kenya C 0.275 78 G 0.725 206 284
Nigeria C 0.230 52 G 0.770 174 226
Table 2 Frequencies of INSIG2 genotypes
Total CC GC GG
(N = 947) (N = 94) (N = 413) (N = 440)
White 85 (10.9%) 345 (44.3%) 348 (44.7%)
Black 8 (5.9%) 50 (36.8%) 78 (57.4%)
Asian 0 (0%) 5 (50%) 5 (50%)
Other 1 (4.3%) 13 (56.5%) 9 (39.2%)
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who carried at least one INSIG2 obesity/lipid allele
increased to 3.4 (p = 0.013). Similarly the adjusted odds
ratio for a history of cerebrovascular disease in older
women increased to 5.5 (p = 0.04). The association with
genotype in the models was not significant for history of
hypercholesterolemia.
Discussion and Conclusions
Cardiovascular disease is associated with a number of
risk factors such as smoking, hypercholesterolemia,
hypertension, type 2 diabetes, and abdominal obesity.
Genetic variations may influence susceptibility to these
risk factors, as well as direct susceptibility to CAD or
MI [18,19]. Obesity is a multi-factorial process that is
associated with an increased risk of cardiovascular dis-
ease, suggesting that they may share common determi-
nants. An ideal candidate for such a shared
predisposition is the INSIG2 gene, which may influence
susceptibility through effects on cholesterol metabolism
and/or obesity.
Previous studies have failed to find a significant asso-
ciation between the INSIG2 rs7566605 SNP and history
of CAD/MI [10,14,15]. We cannot determine whether
this is also the case for our population, which consisted
of patients with existing coronary artery disease because
a weakness of the study design is the lack of a control
population without CAD. Given these limitations, no
Table 3 Patient demographics, disease history, and INSIG2 genotypes
Characteristic Total
(N = 947)
CC
(N = 94)
GC
(N = 413)
GG
(N = 440)
p_value Adjusted
p_value
Age, mean, median 64.0, 64 64.2, 64 65.1, 65 63.0, 63 0.0571 1.0000
Female, % 29.4 23.4 28.6 31.4 0.2748 1.0000
Race, %
White 77.7 87.2 80.8 72.7 0.0490 1.0000
Black 14.0 8.5 11.4 17.5
Asian 1.1 0.0 1.2 1.1
Hispanic 7.0 4.3 6.1 8.4
Other 0.3 0.0 0.5 0.2
Height (cm), mean, median 171.3, 173 172.9, 173 171.7, 173 170.6, 171 0.1450 1.0000
Weight (kg), mean, median 87.3, 85 89.1, 87 86.6, 85 87.5, 85 0.4407 1.0000
Body mass index (kg/m2), mean, median 29.7, 29 29.6, 29 29.4, 28 30.1, 29 0.1616 1.0000
Smoking, %
Never 35.3 34.5 36.9 34.0 0.9078 1.0000
Current 24.1 23.0 23.3 25.1
Former 40.6 42.5 39.7 40.9
Patient previously treated with a stent, % 32.4 37.2 30.1 33.5 0.3268 1.0000
History of in-stent restenosis, % 23.3 26.5 22.6 23.1 0.8909 1.0000
Stent type
Coated, % 16.0 19.1 13.1 18.0 0.1020 1.0000
Uncoated, % 9.6 12.8 10.7 8.0 0.2266 1.0000
Prior CABG, %
None 81.4 79.8 80.3 82.6 0.8098 1.0000
One 16.8 19.1 17.5 15.8
More than one 1.8 1.1 2.2 1.6
Acute MI 25.2 23.4 27.5 23.4 0.4472 1.0000
Prior MI, % 24.9 31.5 20.3 27.8 0.0131 0.2882
History Diabetes, % 37.4 29.8 38.0 38.5 0.2716 1.0000
History Cerebrovascular, % 7.0 5.3 9.9 4.8 0.0125 0.2875
History Renal Disease, % 9.9 9.6 9.9 10.0 0.9902 1.0000
History Chest Pain (angina), % 54.3 57.4 53.4 54.5 0.7716 1.0000
History PVD, % 7.5 11.7 8.4 5.7 0.0851 1.0000
History Pulmonary Disease, % 8.1 7.4 8.9 7.5 0.7500 1.0000
History Cancer, % 8.5 9.6 9.9 7.1 0.3235 1.0000
History Hypercholesterolemia, % 79.4 81.7 75.9 82.2 0.0707 1.0000
History Hypertension, % 78.2 81.7 78.5 77.0 0.5931 1.0000
Skelding et al. BMC Cardiovascular Disorders 2010, 10:46
http://www.biomedcentral.com/1471-2261/10/46
Page 4 of 7association was found with CAD/MI severity related
phenotypes including acute MI, history of prior MI,
chest pain, and prior CABG. No association of
rs7566605 was found with the cardiovascular risk factors
hypertension, type 2 diabetes, obesity, or smoking.
The relationship of the INSIG2 obesity/lipid risk allele
("C”) with hyperlipidemia appears to be complex. The
rs7566605 SNP has been associated with a lower preva-
lence of hypercholesterolemia in a study of 885 Japanese
Americans (347 men and 538 women) and 378 Japanese
Table 4 Association of INSIG2 obesity allele and cardiovascular phenotypes by gender and age
Men, Age ≥ 65
Total CC & GC GG Adjusted p-value
Characteristic (N = 290) (N = 171) (N = 119) p_value
Body mass index (kg/m2), mean, median 27.7, 27 27.8, 27 27.6, 27 0.92 1.0000
History Hypercholesterolemia, % 82.6 82.2 83.2 0.83 1.0000
Prior MI, % 28.7 25.7 33.0 0.18 0.7200
Cerebrovascular, % 12.2 14.2 9.3 0.21 0.7200
PVD, % 10.5 14.2 5.1 0.01 0.0500
Men, Age < 65
Total CC & GC GG Adjusted p-value
Characteristic (N = 377) (N = 195) (N = 182) p_value
Body mass index (kg/m2), mean, median 30.5, 30 30.2, 30 30.8, 30 0.30 0.9000
History Hypercholesterolemia, % 77.5 74.6 80.6 0.17 0.8500
Prior MI, % 25.4 22.7 28.3 0.21 0.8500
Cerebrovascular, % 3.5 4.1 2.7 0.46 0.9000
PVD, % 5.6 6.7 4.4 0.33 0.9000
Women, Age ≥ 65
Characteristic Total CC & GC GG p_value Adjusted p-value
(N = 151) (N = 79) (N = 72)
Body mass index (kg/m2), mean, median 29.6, 29 29.5, 29 29.7, 29 0.83 1.0000
History Hypercholesterolemia, % 81.1 78.9 83.3 0.50 1.0000
Prior MI, % 22.7 20.5 25.0 0.53 1.0000
Cerebrovascular, % 8.0 12.8 2.8 0.02 0.1000
PVD, % 8.0 7.7 8.3 0.88 1.0000
Women, Age < 65
Characteristic Total CC & GC GG p_value Adjusted p-value
(N = 127) (N = 61) (N = 66)
Body mass index (kg/m2), mean, median 32.3, 31 31.5, 30 33.1, 32 0.2105 0.8420
History Hypercholesterolemia, % 75.6 67.2 83.1 0.0412 0.2060
Prior MI, % 16.5 12.3 20.3 0.2351 0.8420
Cerebrovascular, % 4.8 5.2 4.5 0.8710 0.8710
PVD, % 5.6 3.4 7.6 0.3204 0.8420
Table 5 Logistic regression risk models for PVD, cerebrovascular disease, and hypercholesterolemia
Characteristic
(age and gender group)
Adjusted Odds
Ratio
(CC & GC/GG)
95%
C.I.
P-
value
Variables used in model
PVD
(men, age >= 65)
3.4 1.3, 8.8 0.013 History of hypercholesterolemia, history of hypertension, cerebrovascular disease,
history of diabetes, BMI
History of
Hypercholesterolemia
(men, age < 65)
0.7 0.4, 1.2 0.23 PVD, history of hypertension, cerebrovascular disease, history of diabetes, BMI
Cerebrovascular disease
(women, age >= 65)
5.5 1.1,
27.7
0.04 History of hypercholesterolemia, PVD, history of diabetes, BMI
History of
Hypercholesterolemia
(women, age < 65)
0.4 0.2, 1.0 0.07 PVD, history of hypertension, cerebrovascular disease, history of diabetes, BMI
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of hypercholesterolemia was lower in Japanese American
women homozygous for the obesity risk allele (GG,
62.2%; GC, 57.1%; CC, 42.1%), but not in the other sub-
jects [13]. No significant differences in BMI, waist cir-
cumference, or percentage body fat were found in either
population. In contrast, in a study of 2,364 Koreans, the
rs7566605 SNP was found to be associated with total
cholesterol levels in a dominant model in females,
although this association did not meet statistical signifi-
cance after performing a Bonferroni correction [12].
Again, no association was found with BMI. Our initial
analysis found a lower percentage of female patients
with a history of hypercholesterolemia who carried at
least one copy of the INSIG2 obesity/lipid risk allele
("C”) that was not significant after correcting multiple
comparisons. However, we did not have access to actual
cholesterol measurements, thus patients with any degree
of hypercholesterolemia were included in the same case
group. Confounding effects of lipid-lowering medication
use may also be important. Future studies addressing
these factors will be needed to fully assess the relation-
ship of the INSIG2 SNP and cholesterol levels.
We also did not find association with BMI. However,
in animal models, the effect of the INSIG2 gene on body
weight was seen with a low cholesterol diet [4]. Diet
composition was not reported or available for our study
or for most studies on BMI.
Our data indicate that the INSIG2 obesity/lipid risk
allele ("C”) was associated with a higher rate of PAD in
older men and an even higher rate of cerebrovascular
disease in older women, suggesting significant age and
gender related effects. Several other variants have also
been related to PAD [20,21], with one sequence variant
on chromosome 9p21 also associated with a variety of
atherosclerotic phenotypes [17,19,22,23]. Relatively few
data is available on the genetic predisposition to CVD
[23,24]. PAD and CVD are both due to an atherosclero-
tic process, yet it is likely that specific molecular differ-
ences result in clinical disease in either the peripheral or
cerebral vasculature. Larger studies on specific cohorts
of patients with PVD and cerebrovascular disease will be
needed to replicate our findings for INSIG2.
How the specific SNP sequences in the INSIG2 gene
alter the function of the INSIG2 RNA and/or protein to
increase the risk for PAD and CVD is not known. The
INSIG2 SNP is located about 10,000 bases upstream
from the coding region, so is likely to be involved in
regulating the level of RNA and therefore the amount of
protein produced. Future studies will be required to
determine the molecular mechanism by which the speci-
fic INSIG2 DNA variants affect gene function.
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